-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In the KEYNOTE-048 trial, pembrolizumab was effective
in relapsing/metastatic head and neck squamous cell carcinoma with or without chemotherapy.
The long-term efficacy and progression-free survival of the trial after the trial are treated on the line
.
In this trial, patients were randomized (1:1:1) to pembrolizumab, pembrolizumab + chemotherapy, or cetuximab + chemotherapy
.
Stratified efficacy was evaluated
based on PD-L1 combined positive score (CPS) ≥ 20 points, CPS ≥ 1 score and the general population.
Overall survival assessment: A, D, PD-L1 CPS≥ 20 points; B, E, PD-L1 CPS≥ 1 GROUP; C, D, the total population
Median follow-up was 45.
0 months (IQH range 41.
0–49.
2 months; n=882）
。 As of 18 February 2020, pembrolizumab therapy improved overall survival in patients with PD-L1 CPS≥ 20 points (HR 0.
61) and CPS≥1 (HR 0.
74), and in the general population, pembrolizumab monotherapy was non-inferior (HR 0.
81).
Pembrolizumab + chemotherapy improved overall survival in PD-L1 CPS≥ 20 points (HR 0.
61), CPS≥1 score (HR 0.
74), and the general population (HR 0.
71
).
PFS2 assessment: A, D, PD-L1 CPS≥ 20 point population; B, E, PD-L1 CPS≥ 1 GROUP; C, D, the total population
The objective response rate of the second course of pembrolizumab was 27.
3%.
Pylimizumab treatment improved posterior progression-free survival (PFS2) in patients with PD-L1 CPS≥ 20 (HR 0.
64) and CPS≥1 (HR 0.
79); Pembrolizumab + chemotherapy improved PFS2
in PD-L1 CPS≥ 20 (HR 0.
64), CPS≥1 score (HR 0.
66), and general population (HR 0.
73).
Overall, at four-year follow-up, first-line pembrolizumab and pembrolizumab combination chemotherapy continued to show superior survival benefits
over cetuximab plus chemotherapy in relapsed/metastatic head and neck squamous cell carcinoma.
Original source:
Kevin J.
Harrington, et al.
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.
Journal of Clinical Oncology.
October 11, 2022.
https://ascopubs.
org/doi/full/10.
1200/JCO.
21.
02508
